In this context, PCSK9 inhibitors have shown promising potential to enhance immune responses, especially when used in combination with immune checkpoint inhibitors.[3, 4, 5, 6, 7, 8] Altered levels of PCSK9 have also been observed in patients with viral infections, and in vitro studies suggest that PCSK9 inhibitors could provide protective benefits against diseases like dengue and SARS‐CoV‐2 infections, sepsis, and septic shock.[9, 10, 11, 12, 13] Emerging evidence also points to PCSK9 as a potential biomarker and therapeutic target in neurodegenerative diseases. This evidence concerns the gene PCSK9 and Sepsis.